Navigation Links
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Date:9/17/2007

/Aclasta. Such forward- looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Reclast/Aclasta will be approved for sale, or for any additional indications or labeling in any market, or that Reclast/Aclasta will reach any particular level of sales. In particular, management's expectations regarding Reclast/Aclasta could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected additional analysis of existing clinical data, and unexpected new clinical data; competition in general; government, industry, and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; as well as the additional factors discussed in Novartis AG's Form 20-F filed with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes JINS MEME,s ... Co., Ltd. will launch JINS MEME "ACADEMIC PACK" in late ... $5,000 (without tax /including two pairs of JINS MEME and ... solution of "JINS MEME" to academic researchers, and it enables ... electrooculography and six-axis sensors without API. (*Physiological data that can ...
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 26, 2014 /PRNewswire/ ... AEX: PHIA) today announced expanded availability of ... including DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ... of these solutions now available in the U.S., ... global markets, the portfolio offers Philips, customers innovative ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Possible by Early Investment by Cystic Fibrosis ... ... Gilead Sciences,Inc., one of the world,s largest biopharmaceutical companies, and Parion,Sciences, ... a compound that could become an important,new drug in treating the ...
... DIEGO, Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... development company,focused on commercializing proprietary product candidates ... today announced that the U.S. Food and,Drug ... for ANX-510,or CoFactor(R) injection, which is currently ...
Cached Medicine Technology:Promising Cystic Fibrosis Compound on Track for Development 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:11/27/2014)... (PRWEB) November 27, 2014 An inventor ... an embarrassing fact of life, and she wants to ... few minutes later, I decided that there needed to ... she said. , Easy to use and producible in ... in a woman’s private areas throughout the day. It ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
(Date:11/27/2014)... November 27, 2014 Nearly 1,100 ... filed in a consolidated litigation now underway in ... , Documents recently updated in the Philadelphia Court ... the state proceeding, all of which involve a ... other psychiatric conditions. Many of the cases in ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter ... brains seem pre-wired to acquire a second language, new research ... tongue will likely gain a brain boost, the small study ... after learning," said study co-author Ping Li, co-director of the ... But it,s even more interesting, Li said, that "the brain ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... KINGSTON, R.I. -October 27, 2009Two University of Rhode Island ... discovered a technology that can detect cancerous tumors and ... cells surrounding them, thereby significantly reducing side effects. The ... grants in four years. In addition, a number of ...
... developing a range of miniaturised wearable and track-side sensors, ... British athletes improve their performance on the world stage, ... will be officially launched tomorrow (28 October 2009). ... Sensing (ESPRIT) project is funded by the EPSRC and ...
... less of a mystery, study finds. , TUESDAY, Oct. 27 ... the progression of cancer by stimulating a pathway inside cells. ... treatment of cancer, which has been linked to alcohol use ... connected to colon and breast cancer, although it,s not known ...
... N.C., Oct. 27 In conjunction with National Respiratory Care ... support and comfort industry, is proud to promote the results ... with CPAP patients daily. One of the most common ... their CPAP mask, as a result of the mask pressing ...
... SAN DIEGO, Oct. 27 Amira ... discovery and early development of new drugs to treat inflammatory ... present a company overview at the 8th Annual BIO Investor ... on Thursday, October 29, at the Palace Hotel in San ...
... Reform Included in Health Care Reform Le g ... meaningful medical liability reform and agree that changes to our ... care reform legislation passed by the Congress, according to a ... and Access. , "The HCLA poll clearly shows that ...
Cached Medicine News:Health News:URI research couple's method targets cancerous tumors 2Health News:URI research couple's method targets cancerous tumors 3Health News:URI research couple's method targets cancerous tumors 4Health News:Major research collaboration will improve British athletes' performance on world stage 2Health News:Major research collaboration will improve British athletes' performance on world stage 3Health News:Mapping the Link Between Alcohol, Cancer 2Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 2Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 3Health News:New Poll Shows Americans Want Medical Liability Reform 2
... For treatment of carpal tunnel syndrome, mild ... following cast removal. The perforated suede ... the wrist, wicking away moisture for long ... metal splint prevents painful wrist flexion, and ...
... orthotic elbow system that can be used in ... proximal ulnar fractures or post reconstructive surgery where ... highly flexible system that provides you with a ... that best fits your patients needs. Two ...
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Worn by many professional athletes, EpiTrain is our most popular elbow support....
Medicine Products: